Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Return on Sales (2019 - 2023)

Historic Return on Sales for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to 2.91%.

  • ADC Therapeutics' Return on Sales fell 29100.0% to 2.91% in Q4 2023 from the same period last year, while for Dec 2023 it was 2.91%, marking a year-over-year decrease of 29100.0%. This contributed to the annual value of 0.73% for FY2022, which is 65947300.0% up from last year.
  • According to the latest figures from Q4 2023, ADC Therapeutics' Return on Sales is 2.91%, which was down 29100.0% from 3.13% recorded in Q3 2023.
  • ADC Therapeutics' Return on Sales' 5-year high stood at 0.0% during Q4 2022, with a 5-year trough of 5420171.9% in Q3 2021.
  • Over the past 5 years, ADC Therapeutics' median Return on Sales value was 15.49% (recorded in 2021), while the average stood at 309096.67%.
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by 2000000000bps in 2021, then soared by 2000000000bps in 2022.
  • Over the past 5 years, ADC Therapeutics' Return on Sales (Quarter) stood at 157.91% in 2019, then plummeted by -88709bps to 140234.48% in 2020, then soared by 100bps to 51.77% in 2021, then skyrocketed by 100bps to 0.0% in 2022, then tumbled by -1251162430bps to 2.91% in 2023.
  • Its Return on Sales was 2.91% in Q4 2023, compared to 3.13% in Q3 2023 and 2.5% in Q2 2023.